



HAL
open science

Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19

Hawraa Issa, Ali H Eid, Bassam Berry, Vahideh Takhviji, Abbas Khosravi, Sarah Mantash, Rawan Nehme, Rawan Hallal, Hussein Karaki, Kawthar Dhayni, et al.

► To cite this version:

Hawraa Issa, Ali H Eid, Bassam Berry, Vahideh Takhviji, Abbas Khosravi, et al.. Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19. *Frontiers in Medicine*, 2021, 8, pp.620990. 10.3389/fmed.2021.620990 . hal-04645226

HAL Id: hal-04645226

<https://hal.science/hal-04645226v1>

Submitted on 11 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19

Hawraa Issa^{1,2}, Ali H. Eid^{3,4}, Bassam Berry⁵, Vahideh Takhviji⁶, Abbas Khosravi⁶, Sarah Mantash¹, Rawan Nehme¹, Rawan Hallal¹, Hussein Karaki¹, Kawthar Dhayni^{1,7}, Wissam H. Faour⁸, Firas Kobeissy⁹, Ali Nehme¹⁰ and Kazem Zibara^{1*}

OPEN ACCESS

Edited by:

Reza Lashgari,
Institute for Research in Fundamental
Sciences, Iran

Reviewed by:

Dongdong Li,
Sichuan University, China
Scott Wesley Long,
Houston Methodist Hospital,
United States

*Correspondence:

Kazem Zibara
kzibara@ul.edu.lb

Specialty section:

This article was submitted to
Infectious Diseases - Surveillance,
Prevention and Treatment,
a section of the journal
Frontiers in Medicine

Received: 26 October 2020

Accepted: 22 February 2021

Published: 18 March 2021

Citation:

Issa H, Eid AH, Berry B, Takhviji V, Khosravi A, Mantash S, Nehme R, Hallal R, Karaki H, Dhayni K, Faour WH, Kobeissy F, Nehme A and Zibara K (2021) Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19. *Front. Med.* 8:620990. doi: 10.3389/fmed.2021.620990

¹ PRASE and Biology Department, Faculty of Sciences - I, Lebanese University, Beirut, Lebanon, ² College of Public Health, Phoenicia University, Zahrani, Lebanon, ³ Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar, ⁴ Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha, Qatar, ⁵ Institut Pasteur, Paris 6 University, Paris, France, ⁶ Transfusion Research Center, High Institute for Research and Education in Transfusion, Tehran, Iran, ⁷ EA7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France, ⁸ School of Medicine, Lebanese American University, Byblos, Lebanon, ⁹ Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon, ¹⁰ Department of Human Genetics, McGill University, Montreal, QC, Canada

Coronavirus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the most concerning health problem worldwide. SARS-CoV-2 infects cells by binding to angiotensin-converting enzyme 2 (ACE2). It is believed that the differential response to SARS-CoV-2 is correlated with the differential expression of ACE2. Several reports proposed the use of ACE2 pharmacological inhibitors and ACE2 antibodies to block viral entry. However, ACE2 inhibition is associated with lung and cardiovascular pathology and would probably increase the pathogenesis of COVID-19. Therefore, utilizing ACE2 soluble analogs to block viral entry while rescuing ACE2 activity has been proposed. Despite their protective effects, such analogs can form a circulating reservoir of the virus, thus accelerating its spread in the body. Levels of ACE2 are reduced following viral infection, possibly due to increased viral entry and lysis of ACE2 positive cells. Downregulation of ACE2/Ang (1-7) axis is associated with Ang II upregulation. Of note, while Ang (1-7) exerts protective effects on the lung and cardiovascular system, Ang II elicits pro-inflammatory and pro-fibrotic detrimental effects by binding to the angiotensin type 1 receptor (AT1R). Indeed, AT1R blockers (ARBs) can alleviate the harmful effects associated with Ang II upregulation while increasing ACE2 expression and thus the risk of viral infection. Therefore, Ang (1-7) agonists seem to be a better treatment option. Another approach is the transfusion of convalescent plasma from recovered patients with deteriorated symptoms. Indeed, this appears to be promising due to the neutralizing capacity of anti-COVID-19 antibodies. In light of these considerations, we encourage the adoption of Ang (1-7) agonists and

convalescent plasma conjugated therapy for the treatment of COVID-19 patients. This therapeutic regimen is expected to be a safer choice since it possesses the proven ability to neutralize the virus while ensuring lung and cardiovascular protection through modulation of the inflammatory response.

Keywords: ACE2, SARS-CoV-2, COVID-19, lung pathology, cardiovascular pathology, convalescent plasma (CP), Angiotensin 1-7 (Ang1-7), combination therapy

INTRODUCTION

Starting November 2019, several cases of pneumonia of unknown etiology were reported in Wuhan, China (1). The causal agent was identified as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The newly identified betacoronavirus differs from severe acute respiratory syndrome coronavirus (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV); however, it causes similar symptoms associated with pneumonia (2–4). In contrast to SARS-CoV-1, which caused the 2002 outbreak, SARS-CoV-2 exhibits a higher risk of transmission as evident from the rapid global rise in the number of Coronavirus disease 2019 (COVID-19) cases (2–4). As of mid February 2021, more than 110 million cases have been confirmed, and nearly 2,400,000 deaths were reported globally, with the rapid increase of numbers in many countries.

SARS-CoV-2 is mainly transmitted from person to person through respiratory droplets, contact, aerosol, or oral-fecal transmission (5, 6). While most reported COVID-19 cases present mild to moderate pathology, 20% of infected patients may develop severe disease and need intensive care (7–12). Severe cases progress to acute respiratory distress syndrome (ARDS) after 8–9 days of symptoms onset (1). ARDS seen in severe COVID-19 cases is characterized by difficulty in breathing and low blood oxygen level, leading to respiratory failure, which is the main cause of death in 70% of fatal COVID-19 cases (8–10). Plasma analysis of severe cases showed a massive release of cytokines by the immune system (cytokine storm) in response to the viral infection and/or potential secondary bacterial and fungal infections (8, 9). This uncontrolled inflammation induced by SARS-CoV-2 infection results in multi-organ damage, leading to organ failure (10).

Abbreviations: $\alpha 7$ -nAChR, $\alpha 7$ subtype of the nicotine acetylcholine receptor; ARDS, Acute respiratory distress syndrome; Ang I, angiotensin I; Ang (1-7), angiotensin (1-7); Ang (1-9), angiotensin (1-9); Ang II, angiotensin II; ACE, angiotensin converting enzyme; ACE2, angiotensin converting enzyme 2; ACEIs, angiotensin converting enzyme inhibitors; AT1R, angiotensin type 1 receptor; AT2R, angiotensin type 2 receptor; ARBs, angiotensin type 1 receptor blockers; Abs, antibodies; CV, cardiovascular; CVD, cardiovascular disease; CFR, case fatality rate; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; CP, convalescent plasma; COVID-19, coronavirus disease-2019; CRP, C-reactive protein; DPP4, dipeptidyl peptidase 4; FP, fusion peptide; MasR, G-coupled receptor Mas; GPCR, G protein-coupled receptors; HR1, heptad repeat region 1; HR2, heptad repeat region 2; HT, hypertension; MERS-CoV, Middle East respiratory syndrome coronavirus; NS, non-specified; PCT, pro-calcitonin; RBD, receptor-binding domain; rhACE2, recombinant human ACE2; RAS, renin angiotensin system; RASIs, renin angiotensin system inhibitors; SARS-CoV-1, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; S protein, spike protein; S1, S protein subunit 1; S2, S protein subunit 2; TMPRSS2, transmembrane protease serine 2.

Certain groups of the population are more susceptible to SARS-CoV-2 infection (11–14). The case fatality rate (CFR) seems to be age-dependent, with a higher percentage in the elderly, especially men. SARS-CoV-2 may have a higher transmissibility than SARS-CoV-1 and MERS-CoV (1, 8, 15, 16). Patients with pre-existing comorbidities such as chronic obstructive pulmonary disease (COPD), cardiovascular diseases, hypertension and type 2 diabetes mellitus, are more likely to display a severe course and to have higher mortality rates (13–18).

Initial research on SARS-CoV-2 demonstrated that it binds to host cells using the angiotensin-converting enzyme 2 (ACE2), similar to SARS-CoV-1. SARS-CoV-2 binds to ACE2 proteins as a receptor in bats, civet cats, swine, cats, ferrets, non-human primates, and humans (16–18).

The binding affinity of SARS-CoV-2 RBD to ACE2 seems stronger than that of SARS-CoV-1. Besides, SARS-CoV-2 has evolved to use a wide array of host proteases (transmembrane protease serine 2 (TMPRSS2), cathepsin L/B, furin, trypsin, etc.) for S-protein priming, thus facilitating cell entry following receptor binding. This may explain the considerably larger global influence of COVID-19 than the initial SARS epidemic of 2003 (19–21). It is worth noting that new SARS-CoV-2 strains, namely the British (B.1.1.7) and South African variants (B.1.351), that emerged toward the end of 2020 show increased transmission capacity, associated with increased interaction force between Spike and ACE2 proteins due to viral mutations (22, 23). In addition, the RBD/ACE2 mediated SARS-CoV-2 entry into cells is followed by subsequent downregulation of surface ACE2 expression (24). Several reports indicate that the reduction in ACE2 function influences blood pressure, perturbs fluid/electrolyte balance, enhances inflammation, and vascular permeability in the airways, and facilitates the development of multiorgan damage from SARS-CoV-2 infections (25–29). Consequently, ACE2 appears as a critical factor in understanding COVID-19 pathology and a potential target for COVID-19 treatment.

ACE2 IS PART OF A COMPLEX SYSTEM

ACE2 is a membrane-bound glycoprotein of 805 amino acids that exhibits 40% identity and 61% similarity to human angiotensin converting enzyme (ACE). Full-length ACE2 consists of a heavily glycosylated N-terminal signal sequence containing the active site, a hydrophobic transmembrane sequence, and a short C-terminal cytoplasmic tail. A soluble and catalytically active form of ACE2 can be also produced by several mechanisms, including the action of ADAMs family members of zinc metalloproteases

(30–33). ACE2 is the main enzyme involved in the production of the Ang (1-7) peptide of the renin-angiotensin system (RAS) (**Figure 1**). The latter comprises successive enzymatic reactions that regulate multiple biological processes, including cellular growth, proliferation, migration, extracellular matrix remodeling, and inflammation. While RAS includes multiple enzymatic axes leading to the production of different bioactive peptides, local tissue effects of RAS are driven mostly by the balance between the pro-inflammatory/pro-fibrotic and anti-inflammatory/anti-fibrotic actions of Ang-II and Ang (1-7), respectively (34, 35) (**Figure 1**).

Ang II is produced by the cleavage of Ang I by the angiotensin-converting enzyme (ACE), and it exerts its pro-inflammatory/pro-fibrotic effects by binding to its angiotensin type 1 receptor (AT1R) (**Figure 1**). On the other hand, ACE2 is the most potent Ang (1-7) generating enzyme. By its single catalytic domain, ACE2 can produce Ang (1-7) directly by cleaving one amino acid from the C-terminal domain of Ang II or indirectly through two successive cleavage reactions from Ang I (36) (**Figure 1**). Of note, Ang II is the preferred substrate for ACE2, with an affinity of 400-fold higher than that of Ang I (37). Hence, Ang-(1-7) production is based on both ACE2 levels and the ACE/ACE2 ratio.

Ang (1-7) exerts its effects by binding to and activating the G-coupled receptor Mas (MasR), which opposes the pro-inflammatory and pro-fibrotic actions of Ang II through AT1R activation (38, 39). Moreover, MasR can inhibit Ang II-mediated actions by hetero-oligomerization and inhibition of AT1R. Ang (1-7) can also exert its protective effects by binding directly to the angiotensin type 2 receptor (AT2R) (40, 41). Interestingly, the AT2R can exert similar protective effects when bound by Ang II (34, 35). Thus, the crucial role of ACE2 in RAS stems from the fact that it cleaves and opposes the action of Ang II (**Figure 1**). Consequently, it has a beneficial role in many diseases such as diabetes and cardiovascular diseases (CVD) (33), as well as in COVID-19 (42).

ROLE OF THE ACE2/ANG (1-7)/MASR AXIS IN PULMONARY PHYSIOLOGY AND PATHOLOGY

RAS gained an increased complexity and appreciation with the identification of local RAS in different tissues, including the brain, kidneys, heart, ovary, pancreas, and the vascular wall, independent of the well-known traditional circulatory RAS. Also, the discovery of additional RAS components (alternative enzymes, receptors, and bioactive angiotensin peptides) has extended the system's role far beyond blood pressure regulation and body electrolyte balance. Indeed, novel actions for each member of the RAS are continuously discovered in physiology and diseases (43).

ACE2 is expressed in human airway epithelia and lung parenchyma, suggesting a role in the regulation of pulmonary physiology (44, 45). A large body of evidence has shown the protective role of the ACE2/Ang (1-7)/MasR axis in several models of lung injury, including SARS-CoV-1 mediated injury


(25, 46). In fact, to protect from severe lung failure, ACE2 is known to inhibit Ang II production, ACE activity, and AT1R activation. Of note, the anti-inflammatory and anti-fibrotic responses of ACE2 are mediated by the production of Ang (1-7) bioactive peptide, which protects against acute lung failure via activation of MasR and AT2R. More specifically, Ang (1-7)/MasR exerts its beneficial effects by inhibiting ERK1/2 and NF- κ B signaling pathways in a rat model of ARDS (47) and a mouse model of chronic allergic lung inflammation (44, 48). Magalhaes et al. also showed that MasR knockout mice failed to attenuate inflammation and pathological lung remodeling and presented aggravated asthma due to disruption of the protective arm of the RAS (49). The same research group confirmed that Ang (1-7) infusion resolved inflammation through correction of eosinophile defective apoptosis leading to lung damage (48). Ang (1-7) drug was also demonstrated to prevent bronchial responsiveness, a hallmark sign of chronic asthma (44).

Dysregulation of ACE/ACE2 balance leads to impaired lung function due to inflammation, fibrosis, and lung edema. The latter phenomenon is most probably induced via increasing pulmonary blood vessels' permeability (25, 46, 47). Elevated ACE concentrations have been detected in many potentially fibrotic lung diseases, including idiopathic pulmonary fibrosis (50) and ARDS (51, 52). Similar pro-fibrotic effects were also observed in a mouse model of ARDS using the MasR antagonist A779 (53). Moreover, Ang II has been shown to stimulate lung fibroblast proliferation and procollagen production by stimulating AT1R and the autocrine action of TGF β . Of interest, *losartan* (AT1R blocker) and *ramipril* (ACE inhibitor), and Ang (1-7) were shown to reduce lung collagen deposition in the same study (53, 54). Thus, the protective effects of ACE2 on the lungs can be attributed to the inactivation of the ACE/Ang II/AT1R axis in favor of the ACE2/Ang (1-7)/MasR-AT2R axis (25).

ROLE OF ACE2 IN THE PATHOLOGY OF COVID-19

The expression of ACE2 in human airways and lung tissues highlights its role in respiratory infections, including SARS-CoV-1 and the related human respiratory coronavirus NL63 (55). Although ACE2 is the main door for virus entry, the total ACE2 activity seems to be protective. In fact, several reports mentioned that ACE2 could be downregulated after virus entry and/or host cell lysis, as in SARS-CoV-1. The latter is reported to reduce ACE2 expression at the cell surface as well as the release of active ACE2 ectodomains (56, 57). This fact may further accentuate the pathogenesis of COVID-19, as ACE2 is shown to be protective in several models of lung injury, including SARS-CoV-1 mediated injury (25, 46).

Both SARS-CoV-1 and SARS-CoV-2 use the same receptor, ACE2, to infect cells. Interestingly, SARS-CoV-2 was shown to have a higher affinity for ACE2 than SARS-CoV-1 (58–60). Higher affinity values could be related to the dynamic of infection and the rapid spread that characterize this virus (61). For instance, mutations that increase the infectivity on



RBD could explain why SARS-CoV-2 is more infectious than SARS-CoV-1 (62). Notably, mutations affecting SARS-CoV-2 have also been reported. In fact, by the end of August 2020, the C.1 lineage of SARS-CoV-2 presenting one amino acid substitution, D614G, on the spike protein, among 16 other nucleotide mutations, became the predominant lineage in South Africa (63). Analyses of over 28,000 SARS-CoV-2 spike protein gene sequences revealed that the D614G amino acid substitution facilitates the binding to ACE2 receptor and thus enhances viral replication in human lung epithelial cells and primary human airway tissues. This might account for its increased virulence to the respiratory system (64, 65). In addition, the 501Y.V2 variant that appeared in South Africa in December 2020 showed three important mutations in RBD (K417N, E484K, and N501Y) that are most probably correlated with functional significance (66). Another study on the B.1.1.7 British lineage revealed that the N501Y mutation of the SARS-CoV-2 spike protein is linked with increased interaction with ACE2 receptor, which explains its high infectivity rate (23).

The SARS-CoV-2 entry into target cells is initiated by the binding of the surface unit, S1, of the spike (S) protein to the ACE2 cellular receptor (Figure 2). The entry then requires S protein priming by TMPRSS2 serine proteases, which entails S protein cleavage and allows the fusion of viral and cellular membranes (67). Of note, several studies highlighted TMPRSS2 implication as a critical factor for the spread of clinically relevant viruses, including influenza A and other coronaviruses (68–70). One study conducted on a cohort of Italian patients announced that COVID-19 susceptibility is determined by genetic variability of TMPRSS2 known to be involved in SARS-CoV-2 entry into target cells. In this context, the data showed that in comparison to other European populations, Italians might have a higher level of TMPRSS2 or activity since they show a significant decrease in the deleterious variants of this protein. This can be considered as a risk factor for a more severe illness course (71). TMPRSS2 mediated activation of S protein priming enables viral infection of ACE2 positive cells. This initial phase is associated with viral replication and leads to pyroptosis, an inflammatory form of




FIGURE 2 | ACE2 in the pathology of COVID-19. The novel SARS-CoV-2 infects the cells through binding to its main receptor ACE2. The latter recognizes the RBD of the S1 subunit and allows the endocytosis of the virus (1). Once exposed to the action of proteases, such as the cellular TMPRSS2, the S1 subunit is cleaved away to ensure S protein priming (2). The fusion peptide (FP) of the S2 subunit is thus exposed to the cellular membrane. The FP initiates the fusion of the viral coat to the endosomal membrane enabling the uncoating of the virus (3). Released into the cytoplasm of the host cell, the viral RNA hijacks the cellular machinery to produce novel viral particles (4). Massive viral replication is thought to be linked with pyroptosis (5), an inflammatory form of apoptosis associated with the release of inflammatory mediators that activate various immune cells in order to create a cytokine storm (6) contributing to the pathogenesis of COVID-19. Viral entry and cellular apoptosis lead to ACE2 downregulation (7), thus stimulating the harmful effects of the ACE/Ang II/AT1R axis. Altogether, these processes are translated into tissue injury and multi-organ damage (8) that can evolve into respiratory, cardiac, hepatic, and/or renal failure (9), causing death (10).

apoptosis, inducing lung injury. Of note, the formation of new viruses is also correlated with the induction of a cytokine storm via activation of various immune cells (56, 72).

DIFFERENTIAL RESPONSE TO COVID-19 COULD BE RELATED TO ACE2 EXPRESSION

Severe COVID-19 cases are mostly observed among elderly patients, with males suffering from chronic comorbidities such as cardiovascular and cerebrovascular diseases, diabetes, and others. Recently, it was established that risk factors including age, male sex, and hypertension provide a convenient tool to identify high-risk individuals. Hypertension elucidates the involvement of RAS in the pathogenesis of COVID-19 due to the interplay between SARS-CoV-2 and ACE2 (73–75). It is believed that ACE2 expression pattern in different organs, tissues, and cell types is permissive for the susceptibility of SARS-CoV-2 infection since ACE2 receptor permits coronavirus entry, replication, spread, and pathogenesis (76).

In order to identify the initial reservoirs of SARS-CoV-2, ACE2 expression levels were assessed within the lung and the

upper/lower airway epithelium. ACE2 was expressed at low levels in the respiratory tract, and it was expressed in multiple epithelial cell types across the lower airway, with the highest expression being observed in club epithelial cells in comparison with basal and ciliated epithelial cells (77). ACE2 expression was also detected in alveolar type II cells in the lung parenchyma (77). In fact, alveolar type II cells, which account for only 5% of the alveoli, are essential to maintain lung elasticity and act as progenitors for alveolar type I cells responsible for gas exchange. Thus, SARS-CoV-2 might be responsible for depletion of the alveolar stem cells leading to the development of irreversible lung injury (56, 76). Remarkably, in the upper airway, nasal epithelial cells, including goblet and ciliated cells, showed the highest expression of ACE2 among all investigated cells in the respiratory tree; thus, highlighting their role in facilitating initial viral entry, transmission, and clearance (45, 77). Moreover, ACE2 expression is dynamic and depends on the differentiation status of epithelial cells. For instance, it is worth noting that differentiated epithelial cells expressing a higher level of ACE2 are readily infected in comparison to undifferentiated cells with low ACE2 expression (55). These findings may raise the theoretical assumption that the differential response to COVID-19 in patients could be in some aspects attributed to changes in ACE2 expression.

In this context, it has been reported that long term smokers express high levels of ACE2 receptor (78), namely in type-2 pneumocytes and alveolar macrophages (79), making them at high risk of infection by SARS-CoV-2 (78). This elevated expression occurs through activation of the $\alpha 7$ subtype of the nicotine acetylcholine receptor ($\alpha 7$ -nAChR) (80). This is further highlighted in a recent meta-analysis revealing that patients with a history of smoking, as well as active smokers, recorded a significant severity of COVID-19 (81). In fact, cigarette smoking promotes alterations in the respiratory tract that might increase the risk of viral infections through multiple mechanisms such as impairment of mucociliary clearance, mucus hypersecretion, fibrosis, and dysfunction of the epithelial barrier. These mechanisms are accompanied by alterations in the immune response, eventually harming the function of the lungs, including gas exchange (82–86).

Although different studies have reported the upregulation of ACE2 expression in the lungs of cigarette smokers (78, 87), surprisingly, a very recent study revealed a decrease in the levels of ACE2 receptor in both alveolar and bronchial epithelial cells of mice exposed to cigarette smoking. Additionally, an *in vitro* study on Calu3 human lung cancer cell line treated with cigarette smoke showed no effect on ACE2 levels but effectively inhibited SARS-CoV-2 replication (88). These conflicting results urge for more work to clarify the role of cigarette smoking on ACE2 expression, SARS-CoV-2 infection and its severe respiratory complications.

DIFFERENTIAL RESPONSE TO COVID-19 AND ACE2 EXPRESSION IN CARDIOVASCULAR PATIENTS

RAS dysregulation, highlighted by Ang II upregulation, is associated with the pathogenesis of CVD. RAS inhibitors, such as ACE inhibitors (ACEI) and AT1R blockers (ARBs), are commonly used for the treatment of CVD patients. ACEI are known to downregulate the expression of Ang II, whereas ARBs are known to block Ang II-mediated detrimental effects (41). Due to the beneficial effects for the activation of the ACE2/Ang (1-7) axis, there has been substantial interest in considering the effect of RAS inhibitors on ACE2 expression in patients with CVD. Previous evidence in several animal models indicated that certain ARBs and ACEIs exhibit the ability to increase ACE2 mRNA and protein expression levels in the heart (89, 90). More importantly, ARBs were shown to alter the expression of ACE2 more consistently than ACEI (91). Although some animal studies displayed an elevation in ACE2 expression under the effect of RAS inhibitors (92), other studies did not. In this context, it has been reported that ACEI did not alter the activity of ACE2 *in vitro* (93). In another study, the use of the ACEI *ramipril* or of the ARB *valsartan* did not increase cardiac ACE2 expression in a rat model of myocardial infarction (94).

In contrast to animal models, limited investigation has been conducted in humans to consider the influence of RAS inhibition on the expression of ACE2 (95). In fact, a human study involving patients with hypertension showed higher urinary ACE2 levels


in patients treated with the ARB *olmesartan*, but not with other ARBs or the ACEI *enalapril* (96). Importantly, ACE2 upregulation has been mostly noticed in renal vasculature and in cardiac tissue. However, the outcomes differed depending on the RAS inhibitors used (97). Furthermore, most human studies relied on measuring the soluble ACE2 levels in the blood. It's worth noting that measuring the membrane-bound ACE2 expression *in vivo* is technically challenging. In this regard, an increase in soluble ACE2 levels may refer to a decrease in the membrane-bound form of ACE2. Therefore, the distinction between soluble and membrane-bound ACE2 must be clear (97).

Overall, upregulation of ACE2 expression in CVD patients under ARBs or ACEIs raised several theoretical assumptions that these treatment regimens might put them at a greater risk of infection by SARS-CoV-2 (60, 95).

POSSIBLE SCENARIOS ON USING ACE2-BASED TREATMENTS FOR COVID-19

ACE2 appears as a potential target for COVID-19 treatment based on the fact that it is an entry receptor critically involved in mediating SARS-CoV-2 infection and on its central role in cardiac pathology as well as in lung damage (98). Some reports suggested introducing ACE2 blockers, such as the MLN-4760 chemical inhibitor, or targeted antibodies to disrupt the viral entry into cells (99, 100). This approach could be detrimental to the risk of reducing ACE2 protective and anti-inflammatory activity, which further increases the susceptibility of lungs for more damage. Instead, viral entry could be impaired by protease inhibitors targeting TMPRSS2 protease implicated in SARS-CoV-2 cell entry, without risking the endogenous ACE2 activity (98) (Figure 3).

A better alternative to attenuate the viral load and infection, in comparison with ACE2 antibodies and pharmacological inhibitors, would be to deliver excessive soluble viral receptor analogs in order to intercept the viral binding to the membrane-bound ACE2. The conceptual principle is that soluble ACE2 may act as a trap, competitively binding and neutralizing the virus while rescuing cellular ACE2 activity and protecting the lungs from injury (99). In fact, a fusion protein of recombinant human ACE2 (rhACE2) was reported to show high affinity to SARS-CoV-2 binding domain and to neutralize the virus *in vitro* (101). Furthermore, Monteil et al. recently demonstrated that a clinical-grade rhACE2 is capable of reducing the viral load of SARS-CoV-2 infection in Vero-E6 cells and of blocking its entry into the cells. This study revealed that rhACE2 could inhibit SARS-CoV-2 infections in human organoids, such as the kidneys, during early stages of viral infection (102). Moreover, a clinical pilot study was planned (NCT number: NCT04287686) to deliver soluble rhACE2 infusions in a small COVID-19 patient cohort in China. Nevertheless, this study was withdrawn for non-stated reasons. Regardless, a large phase II clinical trial has been initiated at the beginning of April by the Austrian pharmaceutical company APEIRON to treat COVID-19 patients with APN01-rhACE2, in Austria,



Germany, and Denmark (98). On the other hand, soluble ACE2 appears to have a short half-life and may lack the capacity to overcome massive virus infection. This agent could form a reservoir of circulating viruses, thus increasing its propagation (103–105) (Figure 3).

Altogether, clinical trials using ACE2-based treatments are eagerly awaited to exclude possible adverse effects and to prove their promising potential to enhance the positive outcomes in patients infected with COVID-19.

ARBs TO REDUCE THE SIDE EFFECTS OF ACE2 INHIBITION BY COVID-19

It is believed that SARS-CoV-2 infection may cause an increase in lung injury and severe acute respiratory failure due to ACE2/Ang (1-7) downregulation. In addition, since Ang II is the major substrate of ACE2, inhibition of ACE2 following

viral entry is generally associated with Ang II upregulation as well as activation of the AT1R. In fact, elevated levels of Ang II were reported in the plasma of SARS-CoV-2 infected patients, which were positively correlated with viral load and lung injury. Thus, the harmful effects of COVID-19 could be achieved by inhibiting Ang II-mediated harmful effects (25, 26, 47, 56, 106). Due to its anti-fibrotic and anti-inflammatory properties, ARBs effectively block Ang II-mediated AT1R activation and reduce acute lung injury in patients diagnosed with pneumonia, sepsis, and influenza (107–109). Therefore, ARBs blocking Ang II/AT1R pathway could overcome the adverse effects of ACE2 downregulation by SARS-CoV-2. On the other hand, several studies reported that ARBs beneficial effects could be correlated to the increase of ACE2 expression and activity in patients. Despite the beneficial properties of ACE2/Ang (1-7) axis (96, 110, 111), ACE2 upregulation after ARB treatment may open the door for viral entry, thus increasing the susceptibility of patients to SARS-CoV-2 infection.

Since the treatment of CVD patients is based on ARBs, their discontinuation in COVID-19 patients has been proposed to reduce ACE2 expression and, thus, the risk of a more severe infection associated with the increased viral entry. In fact, interruption of treatment may be more harmful than protective. For instance, discontinuing RAS inhibitors, including ARBs, in patients with an unstable clinical state (hypertension, heart failure, myocardial infarction), may result in a decline in clinical status and higher risks of mortality (60, 95). In fact, ARBs are reported to block Ang II/AT1R axis and to reduce acute lung injury pathogenesis. Interruption of ARBs might increase lung injury since Ang II-mediated AT1R activation is associated with vasoconstriction, oxidative stress, increased fibroproliferative, and inflammatory responses as well as lung oedema (54, 60, 112, 113). Importantly, studies have shown that these drugs can be protective against lung injury in SARS-CoV-1 patients by enhancing the protective arm of RAS (114). Also, retrospective studies showed that patients using ACEIs and ARBs present a lower risk of mortality and develop less severe cases as compared with those using other hypertensive drugs. On the other hand, these treatment regimens do not increase the risk of SARS-CoV-2 infection nor disease severity, as summarized in **Table 1**.

Taken together, more evidence is needed to support the proper use of ARBs for the treatment of COVID-19 and to exclude the risk of an increased viral entry. ARBs play a protective role in CVD patients by reducing the harmful effects of Ang II/AT1R axis while enhancing ACE2/Ang (1-7) protective axis. Therefore, ARB withdrawal can be potentially harmful rather than protective.

COMBINED THERAPY OF ANTI-COVID-19 ANTIBODIES AND ANG (1-7) AGONIST FOR THE TREATMENT OF COVID-19 PATIENTS

Several therapies are being investigated for the treatment of COVID-19 (124). Passive immunotherapy has also been reported as a treatment option to reduce mortality in many infectious viral diseases, including SARS-CoV-1 and severe influenza-related pathologies (125). Transfusion of anti-COVID-19 antibodies from recovered patients appears to be promising in severe patients. Recent studies showed that transfusion of convalescent plasma (CP) containing anti-COVID-19 neutralizing antibodies to COVID-19 critically ill patients, along with the conventional antiviral treatment, is associated with improvement in fever, inflammatory markers, lymphocyte count, viral clearance, and CT findings (126–128). In fact, Shen et al. conducted the first study describing the use of CP in COVID-19 patients. Indeed, 5 ARDS critically ill patients received CP from recovered healthy donors along with antiviral agents and methylprednisolone. All patients showed improvement of inflammatory markers, and the viral load became negative 12 days post transfusion (126). In another trial performed by Ye et al., 5 of 6 COVID-19 patients treated with CP demonstrated decreased pulmonary lesions based on their CT scan (129). Similar findings were reported by two other studies, revealing an overall improvement in clinical outcomes with no single death recorded during the treatment

procedure (128, 130). Noteworthy, all the preliminary studies mentioned in **Table 2** did not have control groups receiving CP alone, and the sample size of patients was generally limited in number. However, these studies established the safety and efficacy of anti-COVID-19 antibodies transfusion in critically ill patients. Therefore, CP was finally approved last August by the FDA as an investigational new drug for patients with life-threatening SARS-CoV-2 infection (144). On this basis, an FDA-initiated study on a cohort of 20,000 COVID-19 patients confirmed the safety of CP with low incidence of adverse events associated with transfusion (142). Recently, CP infusion was recommended during early stages of infection by Zeng et al. In this trial, 6 COVID-19 patients with respiratory failure received standard care along with CP treatment at a median of 21.5 days post-infection. Eventually, all patients tested negative for SARS-CoV-2 at 3 days post-infusion; however, 5 out of these 6 patients died, suggesting that CP is ineffective in reducing mortality in end-stage COVID-19 patients and should be initiated earlier (140). These findings were confirmed by Salazar et al., who reported a higher reduction in mortality rate in patients receiving CP transfusion within 44 hours of their hospitalization (143). These observations might be due to the late clinical deterioration observed in COVID-19 patients, related to hyper-immune attacks and inflammatory reactions, rather than a direct viral-effect since the peak of viral load is observed during the first week of infection (131). All clinical trials using CP for patients infected with SARS-CoV-1 or SARS-CoV-2 are presented in **Table 2**.

On the other hand, it is tempting to propose the use of Ang (1-7) agonists to overcome the harmful effects of SARS-CoV-2 infection in patients. Ang (1-7) has been reported to oppose the harmful effects of Ang II/AT1R axis by binding to MasR or to AT2R. In addition, it was shown to be cardiopulmonary protective through its anti-hypertensive, anti-thrombotic, anti-arrhythmic, and vasodilatory effects (145–147). Moreover, animal studies demonstrated that ARDS is associated with low Ang (1-7) levels and that Ang (1-7) upregulation reduces reactive oxygen species production and inhibits pulmonary fibrosis to control tissue damage. Besides, data showed that Ang (1-7)/MasR axis exhibits anti-inflammatory effects by inhibiting the NF- κ B pathway and by reducing the production of pro-inflammatory cytokines such as TNF- α and IL-6 (53, 113, 148–151). In this context, Ang (1-7) oral formulation was also proved to attenuate the rupture of alveolar walls and behavioral changes in a mice model of elastase-induced emphysema (152).

The pathogenesis of SARS-CoV-2 infection is mediated through over-activation of the inflammatory response and an increased cytokine production (113, 148, 149). This could be related to the inhibition of the anti-inflammatory ACE2/Ang (1-7)/MasR axis by binding of the virus. Therefore, the severity of COVID-19 could be attenuated by Ang (1-7) administration, which may restore the anti-inflammatory response via MasR activation (153). Several Ang (1-7) agonists are available such as AVE-0991 (154), hydroxypropyl β -cyclodextrin (HP β CD)/Ang (1-7) (155, 156), cyclic angiotensin (1-7) (157), CGEN-856, and CGEN-857 (158). In animal models, these agonists exert their

TABLE 1 | The effect of ACEIs and ARBs on COVID-19 patients with CVD.

Study design	Patient population	Outcomes	Institutes	References
Multicenter, retrospective study	<i>N</i> = 476 COVID-19 patients with moderate (<i>n</i> = 352), severe (<i>n</i> = 54), or critical cases (<i>n</i> = 70) HT grup (<i>n</i> = 113) ACEIs/ARBs (51/113) Other drugs (62/113) Non-HT group (<i>n</i> = 363)	Higher incidence of comorbidities in the severe and critical groups as compared to the moderate group Patients receiving ACEIs or ARBs were more likely assigned to the moderate group than to the severe and critical groups	Three hospitals in Wuhan, Shanghai, and Anhui, China	(115)
Multicenter, retrospective study	<i>N</i> = 1128 COVID-19 patients with HT ACEI/ARB group (<i>n</i> = 188) Other drugs group (<i>n</i> = 940)	The use of ACEIs and ARBs in COVID-19 patients with HT is associated with a lower risk of all-cause mortality	Nine hospitals in Hubei, China	(116)
Multicenter, retrospective study	<i>N</i> = 609 COVID-19 patients HT group (<i>n</i> = 311) No treatment (60/311) ARB (76/311) ACEI (99/311) Other drugs (76/311) Non-HT group (<i>n</i> = 298)	Overall in-hospital mortality was 29% 42% among HT patients died in-hospital, after a median of 6 days from admission Patients receiving anti-HT drugs other than RASIs had a higher CCI, with a higher prevalence of COPD and CV comorbidities	Ten Italian hospitals	(117)
Single-center, retrospective study	<i>N</i> = 417 COVID-19 patients HT group (<i>n</i> = 51) No treatment (9/51) ACEI/ARB (17/51) Other drugs (25/51) Non-HT group (<i>n</i> = 366)	RASIs improve the clinical outcomes of COVID-19 patients with HT HT patients could benefit from the persistent or preferential usage of ACEIs and ARBs	Shenzhen Third People's Hospital, Shenzhen, China	(118)
Single-center, retrospective study	<i>N</i> = 251 COVID-19 patients HT group (<i>n</i> = 126) ACEI/ARB (43/126) Other drugs (83/126) Non-HT group (<i>n</i> = 125)	ARB/ACEI group had significantly lower concentrations of CRP and PCT ARB/ACEI group had a lower non-significant proportion of critical patients, and death rate This study supports the use of ARBs/ACEIs in COVID-19 patients with preexisting HT	Hubei Provincial Hospital of Traditional Chinese Medicine (HPHTCM) in Wuhan, China	(119)
Single-center, retrospective study	<i>N</i> = 1,8472 patients COVID-19 positive group (<i>n</i> = 1735) ACEI (116/1735) ARB (98/1735) COVID-19 negative group (<i>n</i> = 16,737) ACEI (1206/16737) ARB (884/16737)	This study supports various guidelines to continue current ACEIs or ARBs treatments during the COVID-19 pandemic This study found no association between ACEIs or ARBs use and COVID-19 test positivity	Cleveland Clinic Health System in Ohio and Florida, USA	(120)
Single-center, retrospective study	<i>N</i> = 1,178 COVID-19 patients HT group (<i>n</i> = 362) ACEI/ARB (115/362) Non-HT group (<i>n</i> = 816)	ACEIs/ARBs are not associated with COVID-19 severity or increased mortality rates This study supports current guidelines and societal recommendations for treating HT during the COVID-19 pandemic	The Central Hospital of Wuhan, China	(121)
Population based case-control study	<i>N</i> = 3,7031 patients COVID-19 positive group (<i>n</i> = 6,272) ARBs (1394/6272) ACEI (1502/6272) COVID-19 negative group (<i>n</i> = 30,759) ARBs (5910/30759) ACEI (6569/30759)	The use of ACEIs and ARBs was more frequent among patients with COVID-19 than among controls No evidence that ACEIs or ARBs affected the risk of COVID-19	Lombardy region, Italy	(122)
Single-center, retrospective study	<i>N</i> = 12,594 patients COVID-19 positive group (<i>n</i> = 5,894) HT (2573/5894) COVID-19 negative group (<i>n</i> = 6,700) HT (1784/6700)	No substantial increase in the likelihood of a positive test for COVID-19 or in the risk of severe COVID-19 among patients who tested positive in association with five common classes of anti-HT medications including ACEIs and ARBs	New York University (NYU) Langone Health system, New York, USA	(123)

This table summarizes different retrospective studies evaluating the effect of ACEIs and ARBs on the risk of SARS-CoV-2 infection and disease severity in patients with preexisting HT. Altogether, the results showed that ACEIs and ARBs do not appear to be associated with a higher risk of SARS-CoV-2 infection, neither with disease severity and mortality. This evidence supports the current guidelines that discourage the discontinuation of ACEIs and ARBs in CVD patients infected with SARS-CoV-2. Of note, patients using ACEIs and ARBs are more likely to develop less severe symptoms and show improved clinical outcomes, reduced concentration of inflammatory markers as well as a lower risk of mortality compared to those using other antihypertensive drugs. In this context, recommendations are addressed toward the preferential use of RASIs for the management of hypertension in COVID-19 patients, all along with standard anti-viral medication. ACEI: angiotensin converting enzyme inhibitors; ARB, angiotensin receptor type 1 blockers; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease-2019; CRP, C-reactive protein; CV, cardiovascular; CVD, cardiovascular disease; HT, hypertension; PCT, pro-calcitonin; RASI, renin-angiotensin system inhibitors; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

TABLE 2 | The effect of convalescent plasma-based therapy on SARS and COVID-19 patients.

Infectious agent	Study design	Patient population	Outcomes	Institutes	References
SARS-CoV-1	Case series	<i>N</i> = 80 SARS patients with radiographic progression and hypoxemia Group 1: patients given CP before day 14 of illness (<i>n</i> = 48) Group 2: patients given CP after 14 days of illness (<i>n</i> = 32) No control group	A higher day 22 discharge rate was observed among patients who were given CP before day 14 of illness (58.3 vs. 15.6%) Overall mortality rate among 80 patients was 12.5%	Prince of Wales Hospital, Hong Kong, China	(131)
SARS-CoV-1	Single-center, retrospective non-randomized study	<i>N</i> = 40 SARS patients having clinical and radiographic deterioration despite methylprednisolone treatment Intervention group: patients given 3 doses of methylprednisolone steroids with CP (<i>n</i> = 19) Control group: patients given 4 or more doses of methylprednisolone (<i>n</i> = 21)	Discharge rate in intervention group was 73.4 vs. 19% in control group Mortality rate in intervention group was 0 vs. 23.8% in control group	Prince of Wales Hospital, Hong Kong, China	(132)
SARS-CoV-1	Case series	<i>N</i> = 40 SARS patients with pneumonia or ARDS Intervention group: patients receiving CP (<i>n</i> = NS) Control group: patients receiving other types of therapy (<i>n</i> = NS)	No mortality cases are reported in the intervention group Three mortality cases are reported in the control group	Medical College of Hong Kong Chinese University, China	(133)
SARS-CoV-1	Case series	<i>N</i> = 8 SARS patients Intervention group: patients receiving CP with antivirals and steroids (<i>n</i> = 3) Control group: patients receiving only antivirals and steroids treatments (<i>n</i> = 5)	Intervention group presents improved serial chest radiographs and decreased body temperature Viral load was no longer detectable after 24h of CP treatment	Taipei Municipal Hoping Hospital (TMHH), Taiwan	(134)
SARS-CoV-1	Cases report	<i>N</i> = 29 SARS patients Intervention group: 74 years old patient receiving CP after antivirals and steroids treatments (<i>n</i> = 1) Control group: younger SARS patients receiving antivirals and steroids treatments only (<i>n</i> = 28)	The patient receiving CP recovered from SARS within 21 days and have a shorter disease course than the control group	Beijing hospital, China	(135)
SARS-CoV-1	Case report	<i>N</i> = 1 SARS patient Intervention group: 57 years old patient receiving CP, antivirals and steroids treatments (<i>n</i> = 1) No control group	Patient showed improved Chest X-ray and decreased body temperature following CP treatment The patient made uneventful recovery	Prince of Wales Hospital, China	(136)
SARS-CoV-2	Cases report	<i>N</i> = 5 COVID-19 patients with ARDS, severe rapid progression pneumonia and continuously high viral load despite antiviral treatment Intervention group: patients receiving CP (<i>n</i> = 5) No control group	Body temperature normalized within 3 days, viral load became negative after 12 days and ARDS resolved in 4 patients out of 5	Shenzhen Third People's Hospital in Shenzhen, China	(126)
SARS-CoV-2	Multicenter, randomized clinical trial	<i>N</i> = 103 COVID-19 patients with severe ARDS, hypoxemia or life-threatening organ failure Intervention group: patients receiving CP in addition to standard treatment (<i>n</i> = 52) Control group: patients receiving standard treatment alone (<i>n</i> = 51)	51.9% of the intervention group showed clinical improvement (defined as patients discharged alive, or reduction in disease severity) vs. 43.1% in the control group Two patients from the intervention group experienced adverse events within hours after transfusion	Seven medical centers in Wuhan, China	(137)
SARS-CoV-2	Cases report	<i>N</i> = 2 COVID-19 patients with severe pneumonia and ARDS Intervention group: patients receiving antivirals and steroids treatments with CP (<i>n</i> = 2) No control group	The patients showed improved oxygenation and chest X-rays with decreased inflammatory markers and viral loads after CP infusion	Yonsei University College of Medicine, Seoul, Korea	(127)

(Continued)

TABLE 2 | Continued

Infectious agent	Study design	Patient population	Outcomes	Institutes	References
SARS-CoV-2	Cases report	<i>N</i> = 10 COVID-19 patients with severe symptoms, respiratory distress, or hypoxemia Intervention group: patients receiving CP in addition to antiviral therapy and supportive care (<i>n</i> = 10) No control group	All patients achieved negative viral load, accompanied with an increase of oxygen saturation, improvement of liver function and alleviation of the overreaction of the immune system after plasma transfusion	Three participating hospitals in Wuhan, China	(128)
SARS-CoV-2	Cases report	<i>N</i> = 6 Critically ill COVID-19 patients with deteriorated symptoms after standard treatment Intervention group: patients receiving CP with anti-viral drug arbutol (<i>n</i> = 6) No control group	No adverse reactions were observed after plasma infusion After CP transfusion 5 of 6 patients showed improvement in the CT scan results All patients were discharged after achieving negative viral load	Wuhan Huoshenshan Hospital, Wuhan, China	(129)
SARS-CoV-2	Cases report	<i>N</i> = 4 COVID-19 patients with severe symptoms including ARDS Intervention group: patients receiving anti-viral and interferon-based drug in addition to CP (<i>n</i> = 4). No control group	All 4 patients achieved negative RT-PCR test results after 3-22 days of transfusion 2 of the 4 patients produced anti-SARS-CoV-2 IgG 14 days after CP transfusion	Dongguan Ninth People's Hospital and Xiangtan Central Hospital, China	(130)
SARS-CoV-2	Single-arm, multicenter trial	<i>N</i> = 46 COVID-19 patients with severe symptoms, including ARDS, low oxygen saturation levels and markedly elevated laboratory bio- markers Intervention group 1: one unit of CP in addition to standards treatment (<i>n</i> = 24) Intervention group 2: two units of CP in addition to standard treatment (<i>n</i> = 21) Intervention group 3: three units of CP in addition to standard treatment (<i>n</i> = 1) No control group	3 patients with important comorbidities died within 7 days of plasma transfusion 23% of survivors showed a clear chest X-ray, and 100% of them had improvement in laboratory biomarkers (C-reactive protein, ferritin and lactate dehydrogenase levels all decreased) after 7 days of transfusion All 43 patients achieved negative viral-load at the end of the study	Two university hospitals and one general hospital in northern Italy	(138)
SARS-CoV-2	Retrospective cohort study	<i>N</i> = 80 Critically ill Covid-19 patients with severe symptoms Intervention group: patients receiving CP along with standard care (including hydroxychloroquine, azithromycin, and lopinavir-ritonavir) (<i>n</i> = 40). Control group: patients receiving standard care only (<i>n</i> = 40)	Improvement in respiratory status achieved in 77.5% of intervention group vs 65% of control group Viral clearance achieved after 28 days of CP infusion in 65% of intervention group vs 55% in the control group Overall survival was 65% with no difference between the two groups	Hamad Medical Corporation (HMC), Qatar	(139)
SARS-CoV-2	Cases report	<i>N</i> = 21 COVID-19 patients with respiratory failure and required intensive care unit admission Intervention group: critically ill patients receiving CP transfusion at a median of 21.5 days' post infection in addition to standards treatment (<i>n</i> = 6) Control group: patients receiving standards treatment only (<i>n</i> = 15)	All the patients in the intervention group tested negative for SARS-CoV-2 RNA by 3 days after infusion 5 out of 6 patients in the intervention group died eventually	First Affiliated Hospital of Zhengzhou University, China	(140)
SARS-CoV-2	Cases report	<i>N</i> = 25 COVID-19 patients with severe and/or life-threatening disease Intervention group: patients receiving anti-inflammatory treatment (including tocilizumab and steroids) and anti-viral drugs, in addition to CP transfusion at median of 10 days' post symptom onset (<i>n</i> = 25) No control group	36% of patients had improvement in the clinical markers after 7 days of transfusion 76% of patients improved from baseline or been discharged after 14 days of transfusion Only one patient from the 25 died from a condition not caused by plasma transfusion	Houston Methodist hospitals, USA	(141)

(Continued)

TABLE 2 | Continued

Infectious agent	Study design	Patient population	Outcomes	Institutes	References
SARS-CoV-2	Multicenter, single arm trial	<i>N</i> = 20 000 COVID-19 patients with severe life-threatening disease Intervention group: patients receiving CP in addition to standard care (<i>n</i> = 20,000) No control group	Overall 7 days' mortality rate was 12.96% The incidence of all serious adverse events related to plasma transfusion are low	FDA-initiated trial including multicenter /national hospitals	(142)
SARS-CoV-2	Multicenter, retrospective, non-randomized, propensity score-matched study	<i>N</i> = 5297 COVID-19 patients Intervention group 1: patients receiving CP with an anti-RBD IgG titer $\geq 1:1350$ (<i>n</i> = 321) Intervention group 2: patients receiving CP with an anti-RBD IgG titer $> 1:150$ but $< 1/1350$ (<i>n</i> = 24) Intervention group 3: patients receiving CP with an anti-RBD IgG titer $< 1:150$ (<i>n</i> = 6) Control group: propensity score-matched controls receiving standard treatment (<i>n</i> = 594)	Mortality was significantly decreased in patients who received plasma with an anti-RBD IgG titer of $\geq 1:1350$ within 72 hours of admission 44 hours after hospitalization is optimal for transfusing COVID-19 patients with high-titer CP in order to prevent mortality 0,6% of patients developed significant adverse events related to plasma transfusion, including allergic reactions	Eight Houston Methodist hospitals, USA	(143)

This table summarizes the majority of clinical trials using CP from recovered patients to treat critically ill patients infected with SARS-CoV-1 or SARS-CoV-2. As reported by several research groups, it seems that CP based therapy is generally associated with a higher discharge rate and a lower mortality risk. Also, this treatment plan is showed to be linked to improved clinical outcomes (body temperature, chest X-ray, oxygen saturation), decreased viral load, and a faster recovery. Growing evidence supports early administration of a high titer anti-COVID-19 antibodies within 72 h post-hospitalization. Analyses regarding the efficacy of CP as a standalone treatment strategy might be limited by the lack of control groups in some human trials and by the co-administration of standard care drugs (anti-inflammatory and anti-viral formulations) together with CP. Even though attention was directed toward the incidence of serious adverse events that can be related to plasma transfusion, it was FDA approved that the risk is low. ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease-2019; CP, convalescent plasma; NS, non-specified; RBD, receptor binding domain; SARS, severe acute respiratory syndrome; SARS-CoV-1, severe acute respiratory syndrome coronavirus 1; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

protective effects, such as vasodilation and improved cardiac remodeling, by binding to MasR, thus mimicking Ang (1-7) effects with high *in vivo* stability (158, 159). Unfortunately, not all Ang (1-7) agonists have been evaluated in human subjects; thus, the safety data is lacking for some of these drugs. Importantly, FDA has granted a pharmaceutical formulation of Ang (1-7), called TXA127, an orphan drug for the treatment of several conditions, including Duchenne muscular dystrophy and pulmonary arterial hypertension (160). Several clinical trials on TXA127 were announced since 2008, some of which were terminated or withdrawn for unknown reasons. For instance, phase I/II clinical trials conducted on cancer patients showed that Ang (1-7) drug is safe, well-tolerated, with no mortality rate and low-grade adverse events such as fatigue, injection site reaction, and flu-like symptoms (161, 162). Interestingly, two double-blind, placebo-control, randomized clinical trials are currently being conducted in Brazil (NCT04633772), Israel (NCT04605887), and New York (NCT04401423) on patients with severe COVID-19 cases. The purpose of these studies is to test the safety and efficacy of TXA127 and to determine whether Ang (1-7) infusions prevent respiratory failure, acute kidney injury, and multi-organ damage due to the management of inflammation. Considering the increasing spread and number of deaths due to COVID-19, it is extremely urgent to evaluate TXA127 and other Ang (1-7) agonists as possible treatments for seriously ill patients.

In the light of the vital role of Ang (1-7) in lung protection and the promising results of anti-COVID-19 antibodies based therapy, combination treatment of Ang (1-7) agonists along

with anti-COVID-19 antibodies may be the ideal therapeutic intervention to alleviate COVID-19 severity (Figure 3).

CONCLUSION AND LIMITATIONS

This review summarizes the treatment strategies targeting ACE2 viral receptor, either directly or indirectly, in the context of COVID-19. Combination therapy using Ang (1-7) and CP in patients infected with SARS-CoV-2 appear to be the most promising alternative. Although the clinical potential of Ang (1-7) agonists has been evidenced in numerous human trials (161, 162); however, its use is limited due to the absence of studies validating its safety and efficacy in COVID-19 patients. In addition, a stable oral Ang (1-7) compound covering a broad range of patients is still lacking (163). Importantly, prolonged exposure to other immuno-suppressor drugs such as corticosteroids might increase the occurrence of secondary infections; thus, evaluating the risk of opportunistic infections in patients treated with Ang (1-7) appear to be of great value (164, 165). Furthermore, steroids possess salt retention activities that might increase the stress over the cardiovascular system.

On the other hand, CP therapy may encounter several challenges that should be taken into consideration despite its proven benefits. One such limitation is its availability; in fact, a shortage in the number of plasma donors could be seen in situations of rapid disease spread resulting in an increased number of infected patients compared to those that have recovered. This would be especially significant and serious for the rare blood group patients. In addition, potential risks can be

directly associated with CP regimen. These risks include, among others, the transmission of harmful pathogens such as HIV, hepatitis B/C, and syphilis. Moreover, other transfusion-related events may occur following CP treatment, including allergic, anaphylactic, or hemolytic reactions, fever, and transfusion circulatory overload (166). Furthermore, transfusion can be associated with transfusion-related acute lung injury (167). Although this complication is not common; however, this possibility should not be ignored since COVID-19 patients are at high risk of developing pulmonary disease (168). Importantly, all studies on CP transfusion as a COVID-19 treatment showed that these severe adverse reactions are infrequent.

The presence of a confounding variable in most CP studies makes it difficult to prove the efficacy of CP transfusion as a stand-alone treatment because patients are mostly receiving a standard care treatment such as anti-viral and anti-inflammatory drugs along with anti-COVID-19 antibodies (128, 141). In addition, the safety and efficiency of CP in pregnant women

and pediatric patients have not been evaluated yet. Noteworthy, several ongoing studies are covering both population groups (169). Finally, since the immune-competent population contributed to the generation of new viral strains in South Africa and the United Kingdom, new adaptations of the virus raise the concern about the possibility of escaping viral neutralization by convalescent antibodies. In this context, a very recent study reported that SARS-CoV-2 has the ability to generate new mutations in its viral spike, which is typically recognized by antibodies, thus facilitating the escape from neutralization (170).

Taken together, more clinical trials are warranted to prove the safety and efficacy as well as the synergistic therapeutic effects of this combination treatment procedure.

AUTHOR CONTRIBUTIONS

AN and KZ proposed the hypothesis and originated this work. All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

REFERENCES

- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet Lond Engl.* (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* (2020) 5:536–44. doi: 10.1038/s41564-020-0695-z
- Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. *Nature.* (2020) 579:265–9. doi: 10.1038/s41586-020-2008-3
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med.* (2020) 382:727–33. doi: 10.1056/NEJMoa2001017
- Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect.* (2020) 9:386–9. doi: 10.1080/22221751.2020.1729071
- van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *N Engl J Med.* (2020) 382:1564–7. doi: 10.1056/NEJMc2004973
- Kolifarhood G, Aghaali M, Mozafar Saadati H, Taherpour N, Rahimi S, Izadi N, et al. Epidemiological and clinical aspects of COVID-19; a narrative review. *Arch Acad Emerg Med.* (2020) 8:e41.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet Lond Engl.* (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7
- Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol.* (2004) 136:95–103. doi: 10.1111/j.1365-2249.2004.02415.x
- Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. *Kidney Int.* (2005) 67:698–705. doi: 10.1111/j.1523-1755.2005.67130.x
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med.* (2020) 382:1199–207. doi: 10.1056/NEJMoa2001316
- Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. *J Infect Dev Ctries.* (2020) 14:125–8. doi: 10.3855/jidc.12600
- Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? *Lancet Lond Engl.* (2020) 395:1225–8. doi: 10.1016/S0140-6736(20)30627-9
- Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. *N Engl J Med.* (2020) 382:1663–5. doi: 10.1056/NEJMc2005073
- Guan W-J, Zhong N-S. Clinical characteristics of Covid-19 in China. *Reply.* *N Engl J Med.* (2020) 382:1861–2. doi: 10.1056/NEJMc2005203
- Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature.* (2020) 579:270–3. doi: 10.1038/s41586-020-2012-7
- Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol.* (2020) 5:562–9. doi: 10.1038/s41564-020-0688-y
- Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. *J Virol.* (2020) 94:e00127-20. doi: 10.1128/JVI.00127-20
- Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science.* (2020) 367:1444–8. doi: 10.1126/science.abb2762
- Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci USA.* (2020) 117:7001–3. doi: 10.1073/pnas.2002589117
- Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. *Virus Res.* (2015) 202:120–34. doi: 10.1016/j.virusres.2014.11.021
- Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, et al. Increased resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to antibody neutralization. *BioRxiv Prepr Serv Biol [Preprint].* (2021) doi: 10.1101/2021.01.25.428137
- Santos JC, Passos GA. The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation. *Bioinformatics. [Preprint].* (2021) doi: 10.1101/2020.12.29.424708
- Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell.* (2020) 181:281–92.e6. doi: 10.1016/j.cell.2020.02.058
- Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature.* (2005) 436:112–6. doi: 10.1038/nature03712
- Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med.* (2005) 11:875–9. doi: 10.1038/nm1267

27. Wang K, Gheblawi M, Oudit GY. Angiotensin converting enzyme 2: a double-edged sword. *Circulation*. (2020) 142:426–8. doi: 10.1161/CIRCULATIONAHA.120.047049
28. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. *Exp Physiol*. (2008) 93:543–8. doi: 10.1113/expphysiol.2007.040048
29. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. *Curr Opin Pharmacol*. (2006) 6:271–6. doi: 10.1016/j.coph.2006.03.001
30. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. *J Biol Chem*. (2000) 275:33238–43. doi: 10.1074/jbc.M002615200
31. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, et al. Tumor necrosis factor- α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). *J Biol Chem*. (2005) 280:30113–9. doi: 10.1074/jbc.M505111200
32. Turner AJ, Hooper NM. Angiotensin-converting enzyme 2. In: Barrett AJ, Rawlings ND, Woessner JF, editors. *Handbook of Proteolytic Enzymes*. Elsevier (2004). p. 349–51. doi: 10.1016/B978-0-12-079611-3.50092-6
33. Tikellis C, Thomas MC. Angiotensin-Converting Enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. *Int J Pept*. (2012) 2012:256294. doi: 10.1155/2012/256294
34. Unger T, Steckelings UM, Santos RS dos. *The Protective Arm of the Renin Angiotensin: Functional Aspects and Therapeutic Implications*. Academic Press (2015). p. 316.
35. Simões e Silva AC, Pinheiro S, Pereira R, Ferreira A, Santos R. The therapeutic potential of Angiotensin-(1-7) as a novel renin-angiotensin system mediator. *Mini-Rev Med Chem*. (2006) 6:603–609. doi: 10.2174/138955706776876203
36. Turner AJ, Tipnis SR, Guy JL, Rice G, Hooper NM. ACEH/ACE2 is a novel mammalian metalloproteinase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. *Can J Physiol Pharmacol*. (2002) 80:346–53. doi: 10.1139/y02-021
37. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. *Biochem J*. (2004) 383:45–51. doi: 10.1042/BJ20040634
38. Ferrario CM, Ahmad S, Nagata S, Simington SW, Varagic J, Kon N, et al. An evolving story of angiotensin-II-forming pathways in rodents and humans. *Clin Sci*. (2014) 126:461–9. doi: 10.1042/CS20130400
39. Santos RAS, Simoes e Silva AC, Maric C, Silva DMR, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *Proc Natl Acad Sci USA*. (2003) 100:8258–63. doi: 10.1073/pnas.1432869100
40. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, et al. G-Protein-coupled receptor mas is a physiological antagonist of the Angiotensin II Type 1 receptor. *Circulation*. (2005) 111:1806–13. doi: 10.1161/01.CIR.0000160867.23556.7D
41. Nehme A, Zibara K. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection? *Hypertens Res*. (2017) 40:903–9. doi: 10.1038/hr.2017.65
42. Wehbe Z, Hammoud S, Soudani N, Zaraket H, El-Yazbi A, Eid AH. Molecular insights into SARS COV-2 interaction with cardiovascular disease: role of RAAS and MAPK signaling. *Front Pharmacol*. (2020) 11:836. doi: 10.3389/fphar.2020.00836
43. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. *Physiol Rev*. (2006) 86:747–803. doi: 10.1152/physrev.00036.2005
44. Magalhães GS, Rodrigues-Machado MG, Motta-Santos D, Silva AR, Caliarí MV, Prata LO, et al. Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. *Br J Pharmacol*. (2015) 172:2330–42. doi: 10.1111/bph.13057
45. Nehme A, Cerutti C, Dhauadi N, Gustin MP, Courand P-Y, Zibara K, et al. Atlas of tissue renin-angiotensin-aldosterone system in human: a transcriptomic meta-analysis. *Sci Rep*. (2015) 5:10035. doi: 10.1038/srep10035
46. Imai Y, Kuba K, Penninger JM. Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. *Cell Mol Life Sci CMLS*. (2007) 64:2006–12. doi: 10.1007/s00018-007-6228-6
47. Li Y, Zeng Z, Cao Y, Liu Y, Ping F, Liang M, et al. Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF- κ B signaling pathways. *Sci Rep*. (2016) 6:27911. doi: 10.1038/srep27911
48. Magalhães GS, Barroso LC, Reis AC, Rodrigues-Machado MG, Gregório JF, Motta-Santos D, et al. Angiotensin-(1-7) promotes resolution of eosinophilic inflammation in an experimental model of asthma. *Front Immunol*. (2018) 9:58. doi: 10.3389/fimmu.2018.00058
49. Magalhães GS, Rodrigues-Machado MG, Motta-Santos D, Alenina N, Bader M, Santos RA, et al. Chronic allergic pulmonary inflammation is aggravated in angiotensin-(1-7) Mas receptor knockout mice. *Am J Physiol Lung Cell Mol Physiol*. (2016) 311:L1141–8. doi: 10.1152/ajplung.00029.2016
50. Specks U, Martin WJ, Rohrbach MS. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. *Am Rev Respir Dis*. (1990) 141:117–23. doi: 10.1164/ajrccm/141.1.117
51. Fourrier F, Chopin C, Wallaert B, Mazurier C, Mangalaboyi J, Durocher A. Compared evolution of plasma fibronectin and angiotensin-converting enzyme levels in septic ARDS. *Chest*. (1985) 87:191–5. doi: 10.1378/chest.87.2.191
52. Idell S, Kueppers F, Lippmann M, Rosen H, Niederman M, Fein A. Angiotensin converting enzyme in bronchoalveolar lavage in ARDS. *Chest*. (1987) 91:52–6. doi: 10.1378/chest.91.1.52
53. Chen Q, Yang Y, Huang Y, Pan C, Liu L, Qiu H. Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury. *J Surg Res*. (2013) 185:740–7. doi: 10.1016/j.jss.2013.06.052
54. Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, et al. Angiotensin II and the fibroproliferative response to acute lung injury. *Am J Physiol Lung Cell Mol Physiol*. (2004) 286:L156–64. doi: 10.1152/ajplung.00313.2002
55. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. *J Virol*. (2005) 79:14614–21. doi: 10.1128/JVI.79.23.14614-14621.2005
56. Rivellese F, Prediletto E. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. *Autoimmun Rev*. (2020) 19:102536. doi: 10.1016/j.autrev.2020.102536
57. Wu Y. Compensation of ACE2 function for possible clinical management of 2019-nCoV-Induced acute lung injury. *Virology*. (2020) 35:256–8. doi: 10.1007/s12250-020-00205-6
58. Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. *Immunity*. (2020) 52:731–3. doi: 10.1016/j.immuni.2020.04.003
59. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*. (2020) 367:1260–3. doi: 10.1126/science.abb2507
60. Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. *eLife*. (2020) 9:e57278. doi: 10.7554/eLife.57278
61. Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: an *in silico* analysis. *EXCLI J*. (2020) 19:410–7. doi: 10.17179/excli2020-1167
62. Chen J, Wang R, Wang M, Wei G-W. Mutations strengthened SARS-CoV-2 infectivity. *J Mol Biol*. (2020) 432:5212–26. doi: 10.1016/j.jmb.2020.07.009
63. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell*. (2020) 182:812–27.e19. doi: 10.1016/j.cell.2020.06.043
64. Plante JA, Liu Y, Xia H, Johnson BA, Lokugamage KG, et al. Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility. *BioRxiv Prepr Serv Biol [Preprint]*. (2020) doi: 10.1101/2020.09.01.278689
65. Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. *BioRxiv Prepr Serv Biol [Preprint]*. (2020) doi: 10.1101/2020.06.12.148726

66. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *Epidemiology MedRxiv [Preprint]*. (2020) doi: 10.1101/2020.12.21.20248640
67. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. (2020) 181:271–80.e8. doi: 10.1016/j.cell.2020.02.052
68. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Krämer-Kühl A, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. *J Virol*. (2013) 87:5502–11. doi: 10.1128/JVI.001232-13
69. Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *J Virol*. (2011) 85:4122–34. doi: 10.1128/JVI.02232-10
70. Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagata N. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. *J Virol*. (2019) 93:e01815-18. doi: 10.1128/JVI.01815-18
71. Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. *Nat Commun*. (2020) 11:4059. doi: 10.1038/s41467-020-17892-0
72. Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. *J Autoimmun*. (2020) 112:102463. doi: 10.1016/j.jaut.2020.102463
73. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. *Crit Care Lond Engl*. (2020) 24:108. doi: 10.1186/s13054-020-2833-7
74. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin-angiotensin system blockers. *Diabetes Metab Syndr*. (2020) 14:283–7. doi: 10.1016/j.dsx.2020.03.016
75. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. *Pol Arch Intern Med*. (2020) 130:304–9. doi: 10.20452/pamw.15272
76. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med*. (2020) 14:185–92. doi: 10.1007/s11684-020-0754-0
77. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat Med*. (2020) 26:681–7. doi: 10.1038/s41591-020-0868-6
78. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco smoking increases the lung gene expression of ACE2, the Receptor of SARS-CoV-2. *Am J Respir Crit Care Med*. (2020) 201:1557–9. doi: 10.1164/rccm.202003-0693LE
79. Kashyap VK, Dhasmana A, Massey A, Kotnala S, Zafar N, Jaggi M, et al. Smoking and COVID-19: adding fuel to the flame. *Int J Mol Sci*. (2020) 21:6581. doi: 10.3390/ijms21186581
80. Russo P, Bonassi S, Giacconi R, Malavolta M, Tomino C, Maggi F. COVID-19 and smoking: is nicotine the hidden link? *Eur Respir J*. (2020) 55:2001116. doi: 10.1183/13993003.01116-2020
81. Gülsen A, Yigitbas BA, Uslu B, Drömann D, Kilinc O. The effect of smoking on COVID-19 symptom severity: systematic review and meta-analysis. *Pulm Med*. (2020) 2020:7590207. doi: 10.1101/2020.08.15.20102699
82. Lawrence H, Hunter A, Murray R, Lim WS, McKeever T. Cigarette smoking and the occurrence of influenza - systematic review. *J Infect*. (2019) 79:401–6. doi: 10.1016/j.jinf.2019.08.014
83. Duffney PF, Embong AK, McGuire CC, Thatcher TH, Phipps RP, Sime PJ. Cigarette smoke increases susceptibility to infection in lung epithelial cells by upregulating caveolin-dependent endocytosis. *PLoS ONE*. (2020) 15:e0232102. doi: 10.1371/journal.pone.0232102
84. Duffney PF, McCarthy CE, Nogales A, Thatcher TH, Martinez-Sobrido L, Phipps RP, et al. Cigarette smoke dampens antiviral signaling in small airway epithelial cells by disrupting TLR3 cleavage. *Am J Physiol Lung Cell Mol Physiol*. (2018) 314:L505–13. doi: 10.1152/ajplung.00406.2017
85. Staudt MR, Salit J, Kaner RJ, Hollmann C, Crystal RG. Altered lung biology of healthy never smokers following acute inhalation of E-cigarettes. *Respir Res*. (2018) 19:78. doi: 10.1186/s12931-018-0778-z
86. Shastri MD, Shukla SD, Chong WC, Kc R, Dua K, Patel RP, et al. Smoking and COVID-19: what we know so far. *Respir Med*. (2020) 176:106237. doi: 10.1016/j.rmed.2020.106237
87. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett T-L, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. *Eur Respir J*. (2020) 55:2000688. doi: 10.1101/2020.03.18.20038455
88. Tomchaney M, Contoli M, Mayo J, Baraldo S, Shuaizhi L, Cabel CR, et al. Paradoxical effects of cigarette smoke and COPD on SARS-CoV2 infection and disease. *BioRxiv Prepr Serv Biol [Preprint]*. (2020) doi: 10.1101/2020.12.07.413252
89. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. *Hypertension*. (2004) 43:970–6. doi: 10.1161/01.HYP.0000124667.34652.1a
90. Wang X, Ye Y, Gong H, Wu J, Yuan J, Wang S, et al. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. *J Mol Cell Cardiol*. (2016) 97:180–90. doi: 10.1016/j.yjmcc.2016.05.012
91. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation*. (2005) 111:2605–10. doi: 10.1161/CIRCULATIONAHA.104.510461
92. Kow CS, Zaidi STR, Hasan SS. Cardiovascular disease and use of renin-angiotensin system inhibitors in COVID-19. *Am J Cardiovasc Drugs Devices Interv*. (2020) 20:217–21. doi: 10.1007/s40256-020-00406-0
93. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, et al. Myocardial infarction increases ACE2 expression in rat and humans. *Eur Heart J*. (2005) 26:369–75; discussion 322–324. doi: 10.1093/eurheartj/ehi114
94. Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. *Clin Sci Lond Engl*. (2012) 123:649–58. doi: 10.1042/CS20120162
95. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. *N Engl J Med*. (2020) 382:1653–9. doi: 10.1056/NEJMs2005760
96. Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. *Am J Hypertens*. (2015) 28:15–21. doi: 10.1093/ajh/hpu086
97. Danser AHJ, Epstein M, Battle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. *Hypertension*. (2020) 75:1382–5. doi: 10.1161/HYPERTENSIONAHA.120.15082
98. Groß S, Jahn C, Cushman S, Bär C, Thum T. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to clinical implications. *J Mol Cell Cardiol*. (2020) 144:47–53. doi: 10.1016/j.yjmcc.2020.04.031
99. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med*. (2020) 46:586–90. doi: 10.1007/s00134-020-05985-9
100. Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z. Covid-19 infection and mortality: a physiologist's perspective enlightening clinical features and plausible interventional strategies. *Am J Physiol Lung Cell Mol Physiol*. (2020) 318:L1020–22. doi: 10.1152/ajplung.00097.2020

101. Lei C, Qian K, Li T, Zhang S, Fu W, Ding M, et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. *Nat Commun.* (2020) 11:2070. doi: 10.1038/s41467-020-16048-4
102. Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble Human ACE2. *Cell.* (2020) 181:905–13.e7. doi: 10.1016/j.cell.2020.04.004
103. Dimitrov DS. The secret life of ACE2 as a receptor for the SARS Virus. *Cell.* (2003) 115:652–3. doi: 10.1016/S0092-8674(03)00976-0
104. Alhenc-Gelas F, Druke TB. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2. *Kidney Int.* (2020) 97:1091–3. doi: 10.1016/j.kint.2020.04.009
105. Ciaglia E, Vecchione C, Puca AA. COVID-19 infection and circulating ACE2 levels: protective role in women and Children. *Front Pediatr.* (2020) 8:206. doi: 10.3389/fped.2020.00206
106. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci.* (2020) 63:364–74. doi: 10.1007/s11427-020-1643-8
107. Mentz RJ, Bakris GL, Waeber B, McMurray JVV, Gheorghiane M, Ruilope LM, et al. The past, present and future of renin-angiotensin aldosterone system inhibition. *Int J Cardiol.* (2013) 167:1677–87. doi: 10.1016/j.ijcard.2012.10.007
108. Saavedra JM. Angiotensin receptor blockers and COVID-19. *Pharmacol Res.* (2020) 156:104832. doi: 10.1016/j.phrs.2020.104832
109. Fedson DS. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. *Ann Transl Med.* (2016) 4:421. doi: 10.21037/atm.2016.11.03
110. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med.* (2020) 8:e21. doi: 10.1016/S2213-2600(20)30116-8
111. Jakovac H. COVID-19: is the ACE2 just a foe? *Am J Physiol-Lung Cell Mol Physiol.* (2020) 318:L1025–6. doi: 10.1152/ajplung.00119.2020
112. Jia H. Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and inflammatory lung disease. *Shock Augusta Ga.* (2016) 46:239–48. doi: 10.1097/SHK.0000000000000633
113. Wösten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. *J Pathol.* (2011) 225:618–27. doi: 10.1002/path.2987
114. Tan WSD, Liao W, Zhou S, Mei D, Wong W-SF. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. *Curr Opin Pharmacol.* (2018) 40:9–17. doi: 10.1016/j.coph.2017.12.002
115. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, et al. COVID-19 with different severities: a multicenter study of clinical features. *Am J Respir Crit Care Med.* (2020) 201:1380–8. doi: 10.1164/rccm.202002-0445OC
116. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. *Circ Res.* (2020) 126:1671–81. doi: 10.1161/CIRCRESAHA.120.317134
117. Tedeschi S, Giannella M, Bartoletti M, Trapani F, Tadolini M, Borghi C, et al. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19. *Clin Infect Dis.* (2020) 71:899–901. doi: 10.1093/cid/ciaa492
118. Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerg Microbes Infect.* (2020) 9:757–60. doi: 10.1080/22221751.2020.1746200
119. Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study. *Hypertension.* (2020) 76:51–8. doi: 10.1161/HYPERTENSIONAHA.120.15143
120. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of use of angiotensin-converting enzyme inhibitors and Angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). *JAMA Cardiol.* (2020) 5:1020–6. doi: 10.1001/jamacardio.2020.1855
121. Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. *JAMA Cardiol.* (2020) 5:825–30. doi: 10.1001/jamacardio.2020.1624
122. Mancía G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–Angiotensin–aldosterone system blockers and the risk of Covid-19. *N Engl J Med.* (2020) 382:2431–40. doi: 10.1056/nejmoa2006923
123. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–Angiotensin–aldosterone system inhibitors and risk of Covid-19. *N Engl J Med.* (2020) 382:2441–8. doi: 10.1056/nejmoa2008975
124. Kaddoura M, Allbrahim M, Hijazi G, Soudani N, Audi A, Alkalamouni H, et al. COVID-19 therapeutic options under investigation. *Front Pharmacol.* (2020) 11:1196. doi: 10.3389/fphar.2020.01196
125. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J Infect Dis.* (2015) 211:80–90. doi: 10.1093/infdis/jiu396
126. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill patients with COVID-19 with convalescent plasma. *JAMA.* (2020) 323:1582–9. doi: 10.1001/jama.2020.4783
127. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. *J Korean Med Sci.* (2020) 35:e149. doi: 10.3346/jkms.2020.35.e149
128. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci USA.* (2020) 117:9490–6. doi: 10.1073/pnas.2004168117
129. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. *J Med Virol.* (2020) 92:1890–901. doi: 10.1002/jmv.25882
130. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for Critically Ill patients with severe acute respiratory syndrome Coronavirus 2 infection. *Chest.* (2020) 158:e9–e13. doi: 10.1016/j.chest.2020.03.039
131. Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis.* (2005) 24:44–6. doi: 10.1007/s10096-004-1271-9
132. Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clin Microbiol Infect.* (2004) 10:676–8. doi: 10.1111/j.1469-0691.2004.00956.x
133. Nie QH, Luo XD, Hui WL. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome. *World J Gastroenterol.* (2003) 9:1139–43. doi: 10.3748/wjg.v9.i6.1139
134. Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. *J Antimicrob Chemother.* (2005) 56:919–22. doi: 10.1093/jac/dki346
135. Zhou X, Zhao M, Wang FS, Jiang TJ, Li YG, Nie WM, et al. Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area. *Zhonghua yi xue za zhi.* (2003) 83:1018–22.
136. Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. *Hong Kong Med J.* (2003) 9:199–201.
137. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. *JAMA.* (2020) 324:460–70. doi: 10.1001/jama.2020.10044
138. Perotti C, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. a proof of concept single arm multicenter trial. *Haematologica.* (2020) 105:2834–40. doi: 10.3324/haematol.2020.261784
139. Omrani AS, Zaqout A, Baiou A, Daghfal J, Elkum N, Alattar RA, et al. Convalescent plasma for the treatment of patients with severe coronavirus

- disease 2019: a preliminary report. *J Med Virol.* (2020) 93:1678–86. doi: 10.1002/jmv.26537
140. Zeng Q-L, Yu Z-J, Gou J-J, Li G-M, Ma S-H, Zhang G-F, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. *J Infect Dis.* (2020) 222:38–43. doi: 10.1093/infdis/jiaa228
 141. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al. Treatment of Coronavirus Disease 2019 (COVID-19) patients with convalescent plasma. *Am J Pathol.* (2020) 190:1680–90. doi: 10.1016/j.ajpath.2020.08.001
 142. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. Safety update. *Mayo Clin Proc.* (2020) 95:1888–97. doi: 10.1016/j.mayocp.2020.06.028
 143. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) spike protein IgG. *Am J Pathol.* (2021) 191:90–107. doi: 10.1016/j.ajpath.2020.10.008
 144. Recommendations for Investigational COVID-19 Convalescent Plasma/FDA.7. Available online at: <https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma>
 145. Nehme A, Zouein FA, Zayeri ZD, Zibara K. An update on the tissue renin angiotensin system and its role in physiology and pathology. *J Cardiovasc Dev Dis.* (2019) 6:14. doi: 10.3390/jcdd6020014
 146. Santos RA. Angiotensin-(1-7). *Hypertension.* (2014) 63:1138–47. doi: 10.1161/HYPERTENSIONAHA.113.01274
 147. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. *Am J Respir Crit Care Med.* (2010) 182:1065–72. doi: 10.1164/rccm.200912-1840OC
 148. Rodrigues Prestes TR, Rocha NP, Miranda AS, Teixeira AL, Simoes-e-Silva AC. The anti-inflammatory potential of ACE2/Angiotensin-(1-7)/Mas receptor axis: evidence from basic and clinical research. *Curr Drug Targets.* (2017) 18:1301–13. doi: 10.2174/1389450117666160727142401
 149. Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. *Eur Rev Med Pharmacol Sci.* (2020) 24:4016–26. doi: 10.26355/eurrev_202004_20871
 150. Gwathmey TM, Pendergrass KD, Reid SD, Rose JC, Diz DI, Chappell MC. Angiotensin-(1-7)-Angiotensin-Converting Enzyme 2 attenuates reactive oxygen species formation to Angiotensin II within the cell nucleus. *Hypertension.* (2010) 55:166–71. doi: 10.1161/HYPERTENSIONAHA.109.141622
 151. Klein N, Gembardt F, Supé S, Kaestle SM, Nickles H, Erfinanda L, et al. Angiotensin-(1-7) protects from experimental acute lung injury. *Crit Care Med.* (2013) 41:e334–43. doi: 10.1097/CCM.0b013e31828a6688
 152. Bastos AC, Magalhães GS, Gregório JF, Matos NA, Motta-Santos D, Bezerra FS, et al. Oral formulation angiotensin-(1-7) therapy attenuates pulmonary and systemic damage in mice with emphysema induced by elastase. *Immunobiology.* (2020) 225:151893. doi: 10.1016/j.imbio.2019.12.002
 153. Magalhaes GS, Rodrigues-Machado M da G, Motta-Santos D, Campagnole-Santos MJ, Santos RAS. Activation of Ang-(1-7)/Mas receptor is a possible strategy to treat coronavirus (SARS-CoV-2) infection. *Front Physiol.* (2020) 11:730. doi: 10.3389/fphys.2020.00730
 154. Carvalho MBL, Duarte FV, Faria-Silva R, Fauler B, da Mata Machado LT, de Paula RD, et al. Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats. *Hypertension.* (2007) 50:762–7. doi: 10.1161/HYPERTENSIONAHA.107.094987
 155. Zhang F, Liu J, Li S-F, Song J-X, Ren J-Y, Chen H. Angiotensin-(1-7): new perspectives in atherosclerosis treatment. *J Geriatr Cardiol JGC.* (2015) 12:676–82. doi: 10.11909/j.issn.1671-5411.2015.06.014
 156. Marques FD, Ferreira AJ, Sinisterra RDM, Jacoby BA, Sousa FB, Caliaro MV, et al. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. *Hypertension.* (2011) 57:477–83. doi: 10.1161/HYPERTENSIONAHA.110.167346
 157. Durik M, van Veghel R, Kuipers A, Rink R, Haas Jimoh Akanbi M, Moll G, et al. The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction. *Int J Hypertens.* (2012) 2012:536426. doi: 10.1155/2012/536426
 158. Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. *Hypertension.* (2010) 56:112–20. doi: 10.1161/HYPERTENSIONAHA.110.152942
 159. Povlsen AL, Grimm D, Wehland M, Infanger M, Krüger M. The vasoactive mas receptor in essential hypertension. *J Clin Med.* (2020) 9:267. doi: 10.3390/jcm9010267
 160. National Center for Advancing Translational Sciences. *ANGIOTENSIN 1-7*. Available online at: <https://drugs.ncats.io/substance/IJ3FUK8MOF> (accessed March 04, 2021).
 161. Savage PD, Lovato J, Brosnihan KB, Miller AA, Petty WJ. Phase II Trial of Angiotensin-(1-7) for the treatment of patients with metastatic sarcoma. *Sarcoma.* (2016) 2016:4592768. doi: 10.1155/2016/4592768
 162. Rodgers KE, Oliver J, diZerega GS. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. *Cancer Chemother Pharmacol.* (2006) 57:559–68. doi: 10.1007/s00280-005-0078-4
 163. Machado-Silva A, Passos-Silva D, Santos RA, Sinisterra RD. Therapeutic uses for Angiotensin-(1-7). *Expert Opin Ther Pat.* (2016) 26:669–78. doi: 10.1080/13543776.2016.1179283
 164. van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. *Crit Care Lond Engl.* (2020) 24:696. doi: 10.1186/s13054-020-03400-9
 165. Use of Angiotensin-(1-7) in COVID-19 (NCT04633772). Available online at: <https://clinicaltrials.gov/ct2/show/NCT04633772> (accessed March 04, 2021).
 166. Piyush R, Rajarshi K, Khan R, Ray S. Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. *Open Biol.* (2020) 10:200174. doi: 10.1098/rsob.200174
 167. Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, de la Calle F, Borobia AM, Sánchez-Seco P, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. *Lancet Respir Med.* (2015) 3:554–62. doi: 10.1016/S2213-2600(15)00180-0
 168. Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. *Am J Respir Crit Care Med.* (2007) 176:886–91. doi: 10.1164/rccm.200702-271OC
 169. COVID-19 Treatment Guidelines. Available online at: <https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/blood-derived-products/convalescent-plasma/> (accessed March 04, 2021).
 170. Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, et al. SARS-CoV-2 escape *in vitro* from a highly neutralizing COVID-19 convalescent plasma. *BioRxiv Prepr Serv Biol [Preprint].* (2020) doi: 10.1101/2020.12.28.424451

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Issa, Eid, Berry, Takhviji, Khosravi, Mantash, Nehme, Hallal, Karaki, Dhayni, Faour, Kobeissy, Nehme and Zibara. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.